Short answer
Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on July 21, 2026 reporting Item 8.01 (Other Events). KB801 patient achieved complete closure of a persistent corneal epithelial defect, supporting patentability claims.
Krystal Biotech, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- KB801 patient achieved complete closure of a persistent corneal epithelial defect, supporting patentability claims
- Observation came from a discontinued clinical study advanced toward a pivotal trial
- No safety concerns or serious adverse events observed in treated study patients
- Single-patient result is not clinical-trial efficacy evidence, limiting investment conclusions
- Pivotal-trial results remain the key upcoming catalyst for KB801 valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Krystal Biotech, Inc. 8-K filings
Get the next KRYS 8-K as it lands
Follow KRYS for push alerts, or ask the research agent what this filing means.